Journal
AMERICAN JOURNAL OF PSYCHIATRY
Volume 169, Issue 3, Pages 326-334Publisher
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2011.11020189
Keywords
-
Categories
Funding
- NIDA NIH HHS [K01 DA-020651, K01 DA020651, K02 DA-021863, K02 DA021863, R01 DA -022495, R01 DA022495] Funding Source: Medline
Ask authors/readers for more resources
Objective: There is a strong association between cigarette smoking and schizophrenia. Nicotine's actions in the brain are mediated through nicotinic acetylcholine receptors. Those containing alpha(4) and beta(2) subunits are the most abundant ones in the brain, have the highest affinity for nicotine, and are critical in mediating nicotine's reinforcing properties. Healthy tobacco smokers have significantly higher levels of beta(2)*-nicotinic acetylcholine receptors than do nonsmokers. However, in postmortem studies, smokers with schizophrenia do not show these higher levels. The purpose of this study was to measure beta(2)*-nicotinic acetylcholine receptors in vivo and to relate levels to concurrent behavioral measures of smoking and schizophrenia. Method: By using single-photon emission computed tomography with the beta(2)*-nicotinic acetylcholine receptor agonist radiotracer [I-123]5-IA-85380, the availability of receptors was measured in smokers with schizophrenia (11 men) and matched comparison smokers after 1 week of confirmed smoking abstinence. Results: Smokers with schizophrenia showed significantly lower (21%-26%) beta(2)*-nicotinic acetylcholine receptor availability relative to comparison smokers in the frontal cortex, parietal cortex, and thalamus (in descending order). There was a specific and robust negative correlation between regional beta(2)*-nicotinic acetylcholine receptor availability and negative symptoms. Conclusions: These are the first in vivo findings of lower beta(2)*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. The relationship between beta(2)*-nicotinic acetylcholine receptor availability and negative symptoms may explain the high rates of smoking in schizophrenia and the relationship between smoking and negative symptoms. Findings support the development of medications targeting the beta(2)*-nicotinic acetylcholine receptor system for the treatment of negative symptoms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available